Cargando…
Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications
Patients with non-small cell lung cancer (NSCLC) develop bone metastasis (BoM) in more than 50% of cases during the course of the disease. This metastatic site can lead to the development of skeletal related events (SREs), such as severe pain, pathological fractures, spinal compression, and hypercal...
Autores principales: | Del Conte, Alessandro, De Carlo, Elisa, Bertoli, Elisa, Stanzione, Brigida, Revelant, Alberto, Bertola, Manuela, Spina, Michele, Bearz, Alessandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224636/ https://www.ncbi.nlm.nih.gov/pubmed/35743275 http://dx.doi.org/10.3390/ijms23126832 |
Ejemplares similares
-
The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
por: Bearz, Alessandra, et al.
Publicado: (2022) -
Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer
por: Stanzione, Brigida, et al.
Publicado: (2023) -
Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era
por: De Carlo, Elisa, et al.
Publicado: (2022) -
Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
por: Bertoli, Elisa, et al.
Publicado: (2022) -
Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
por: Bertoli, Elisa, et al.
Publicado: (2023)